Dystrophic Epidermolysis Bullosa - Epidemiology Forecast - 2032

This ‘Dystrophic Epidermolysis Bullosa (DEB) - Epidemiology Forecast - 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology of Dystrophic Epidermolysis Bullosa (DEB) in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Dystrophic Epidermolysis Bullosa (DEB): Disease Understanding

Dystrophic Epidermolysis Bullosa (DEB) Overview

DEB is the major subtype of epidermolysis bullosa (EB). EB is a group of skin diseases causing skin and mucous membrane fragility. The absence of proteins essential for skin integrity leads to skin fragility. EB is classified into four main types and several clinical subtypes. The main classification relates to the skin layer where blisters formation occurs: EB simplex (EBS; intraepidermal layer), junctional EB (JEB; within the lamina lucida of the basement membrane), dystrophic EB (DEB; below the basement membrane), and Kindler's EB (KEB; mixed skin cleavage pattern).

According to the National Institute of Cancer, DEB is a rare inherited disorder in which blisters form on the skin and the moist inner lining of some organs and body cavities. The blisters usually appear at birth and may occur on certain body parts or all over the body leading to scarring in the affected areas and thinning of the skin. DEB comprises four major and several rare sub-types, with the three most common being intermediate dominant DEB, severe recessive DEB, and intermediate recessive DEB.

The signs and symptoms can vary widely among affected people. In mild cases, blistering may primarily affect the hands, feet, knees, and elbows. Severe cases often involve widespread blistering, leading to vision loss, disfigurement, and other serious medical problems.

As per the National Organization for Rare Disease, some EB occurs in an estimated 1 out of every 50,000 live births. The disorder occurs in every racial and ethnic group worldwide and affects both sexes equally.

It is caused by changes in the COL7A1 gene and may be inherited in an autosomal dominant or autosomal recessive manner, depending on the subtype.

Currently, no curative therapy is available. The present treatment focuses on managing symptoms and complications associated with DEB. Non-adhesive bandages and dressings to protect the wound, moisturizers for reducing friction and itching, and medication to relieve pain are used. In addition, some patients need nutritional support, supplements, occupational therapy, and/or surgery, depending on the associated features of the disease. Hence there is an urgent unmet medical need to diagnose better, treat, cure and eradicate this devastating disease.

Dystrophic Epidermolysis Bullosa (DEB) Epidemiology

The Dystrophic Epidermolysis Bullosa (DEB) epidemiology division provides insights into the historical and current patient pool, along with the forecast trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with assumptions undertaken.

Key Findings

The disease epidemiology provides historical and forecasted Dystrophic Epidermolysis Bullosa (DEB) epidemiology segmented as the Diagnosed prevalent cases of Dystrophic Epidermolysis Bullosa, Age-specific cases of Dystrophic Epidermolysis Bullosa, and Type-specific and Severity-specific prevalent cases of Dystrophic Epidermolysis Bullosa. The report includes the incident scenario of Dystrophic Epidermolysis Bullosa (DEB) in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country-wise Dystrophic Epidermolysis Bullosa (DEB) Epidemiology

The epidemiology segment also provides the Dystrophic Epidermolysis Bullosa (DEB) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total diagnosed prevalent cases of Dystrophic Epidermolysis Bullosa (DEB) in the 7MM countries was near 3,500 cases in 2021.

As per the estimates, the United States had the highest diagnosed prevalent cases of Dystrophic Epidermolysis Bullosa (DEB) in 2021. Among the EU5 countries, the United Kingdom had the highest diagnosed prevalent cases of Dystrophic Epidermolysis Bullosa (DEB) with more than 700 cases, followed by Germany in 2021 while Spain had the lowest diagnosed incident cases of Dystrophic Epidermolysis Bullosa (DEB), close to 280 cases in 2021.

Scope of the Report

• The Dystrophic Epidermolysis Bullosa report covers a detailed overview explaining its causes, symptoms and classification, pathophysiology, diagnosis, and treatment patterns.
• The Dystrophic Epidermolysis Bullosa epidemiology report and model provide an overview of the risk factors and global trends of Dystrophic Epidermolysis Bullosa in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report provides insight into the historical and forecasted patient pool of Dystrophic Epidermolysis Bullosa in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
• The report helps recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Dystrophic Epidermolysis Bullosa.
• The report provides the segmentation of Dystrophic Epidermolysis Bullosa epidemiology by diagnosed prevalent cases of Dystrophic Epidermolysis Bullosa in the 7MM.
• The report provides the segmentation of the Dystrophic Epidermolysis Bullosa epidemiology by age-specific cases of Dystrophic Epidermolysis Bullosa in the 7MM.
• The report describes the Dystrophic Epidermolysis Bullosa epidemiology by prevalent cases of Dystrophic Epidermolysis Bullosa based on etiologies in the 7MM.

Report Highlights

• 11-year forecast of Dystrophic Epidermolysis Bullosa epidemiology
• 7MM coverage
• Diagnosed prevalent cases of Dystrophic Epidermolysis Bullosa
• Age-specific cases of Dystrophic Epidermolysis Bullosa
• Type-specific cases of Dystrophic Epidermolysis Bullosa
• Severity-specific cases of Dystrophic Epidermolysis Bullosa

KOL Views

The publisher interviewsed KOLs and obtained SME's opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the indications.

Key Questions Answered

• What are the major factors that will drive the change in the patient population in Dystrophic Epidermolysis Bullosa during the forecast period (2019-2032)?
• What are the key findings about the Dystrophic Epidermolysis Bullosa epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients with Dystrophic Epidermolysis Bullosa across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR is the patient population expected to grow in the 7MM forecast period (2019-2032)?
• What are the disease risk, burdens, and unmet needs of Dystrophic Epidermolysis Bullosa?
• What are the currently available treatments for Dystrophic Epidermolysis Bullosa?

Reasons to Buy

Dystrophic Epidermolysis Bullosa (DEB) epidemiology report will allow the user to:

• Develop business strategies by understanding the trends shaping and driving the global Dystrophic Epidermolysis Bullosa (DEB) market
• Quantify patient populations in the global Dystrophic Epidermolysis Bullosa market to improve product design, pricing, and launch plans
• Understand the magnitude of the Dystrophic Epidermolysis Bullosa population by its diagnosed prevalent cases.
• Understand the magnitude of the Dystrophic Epidermolysis Bullosa population by its age-specific cases.
• Understand the magnitude of the Dystrophic Epidermolysis Bullosa (DEB) population by its type-specific prevalent cases of Dystrophic Epidermolysis Bullosa.
• Understand the magnitude of the Dystrophic Epidermolysis Bullosa (DEB) population by its severity-specific prevalent cases of Dystrophic Epidermolysis Bullosa.
• The Dystrophic Epidermolysis Bullosa (DEB) epidemiology report and model were written and developed by Master's and PhD level epidemiologists.
• The Dystrophic Epidermolysis Bullosa (DEB) Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources.

Key Assessments

• Patient segmentation
• Disease risk and burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032